Renaissance Technologies LLC Has $497,000 Holdings in Abeona Therapeutics Inc (NASDAQ:ABEO)

Renaissance Technologies LLC decreased its position in shares of Abeona Therapeutics Inc (NASDAQ:ABEO) by 33.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 89,237 shares of the biopharmaceutical company’s stock after selling 45,041 shares during the period. Renaissance Technologies LLC owned about 0.21% of Abeona Therapeutics worth $497,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the company. Jane Street Group LLC acquired a new stake in Abeona Therapeutics during the 3rd quarter valued at $84,000. Trexquant Investment LP acquired a new stake in shares of Abeona Therapeutics in the fourth quarter valued at $382,000. JPMorgan Chase & Co. raised its holdings in shares of Abeona Therapeutics by 74.2% in the third quarter. JPMorgan Chase & Co. now owns 67,138 shares of the biopharmaceutical company’s stock valued at $424,000 after buying an additional 28,606 shares during the last quarter. Wellington Management Group LLP acquired a new position in Abeona Therapeutics during the 4th quarter worth about $520,000. Finally, Geode Capital Management LLC grew its holdings in Abeona Therapeutics by 21.7% during the 3rd quarter. Geode Capital Management LLC now owns 465,317 shares of the biopharmaceutical company’s stock worth $2,942,000 after acquiring an additional 83,050 shares during the last quarter. Institutional investors own 80.56% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. HC Wainwright boosted their target price on shares of Abeona Therapeutics from $15.00 to $20.00 and gave the stock a “buy” rating in a research note on Wednesday. StockNews.com raised Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, March 24th. Finally, Oppenheimer began coverage on Abeona Therapeutics in a research note on Wednesday, March 5th. They issued an “outperform” rating and a $16.00 target price for the company. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $18.75.

Insiders Place Their Bets

In related news, CEO Vishwas Seshadri sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $4.78, for a total transaction of $119,500.00. Following the completion of the transaction, the chief executive officer now owns 1,355,322 shares in the company, valued at approximately $6,478,439.16. The trade was a 1.81 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 5.40% of the company’s stock.

Abeona Therapeutics Trading Down 4.5 %

Shares of NASDAQ ABEO opened at $6.56 on Friday. Abeona Therapeutics Inc has a fifty-two week low of $3.93 and a fifty-two week high of $7.32. The firm has a market capitalization of $320.13 million, a P/E ratio of -2.44 and a beta of 1.68. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12. The company’s 50 day simple moving average is $5.09 and its 200 day simple moving average is $5.61.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.19. On average, analysts predict that Abeona Therapeutics Inc will post -1.16 EPS for the current year.

Abeona Therapeutics Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.